TABLE 1.
In vitro activities of 16 antimicrobial agents against 16 clinical isolates of Desulfovibrio spp.
| Agent | MICa (μg/ml)
|
No. of isolatesb
|
||||
|---|---|---|---|---|---|---|
| 50% | 90% | Range | S | I | R | |
| Penicillin G | 16 | 64 | 1–64 | 0 | 1 | 15 |
| Amoxicillin | 32 | 128 | 0.25–128 | ND | ND | ND |
| Amoxicillin-clavulanate | 32 | 64 | 0.25–64 | 7 | 0 | 9 |
| Ticarcillin | 256 | 256 | 2–256 | 5 | 0 | 11 |
| Ticarcillin-clavulanate | 128 | 256 | 2–256 | 7 | 0 | 9 |
| Piperacillin | 256 | 256 | 64–256 | 0 | 1 | 15 |
| Piperacillin-tazobactam | 128 | 256 | 64–256 | 0 | 4 | 12 |
| Cefotaxime | 128 | 128 | 1–128 | 7 | 0 | 9 |
| Cefotaxime-sulbactam | 128 | 128 | 0.06–128 | ND | ND | ND |
| Cefoxitin | 128 | >256 | 32–>256 | 0 | 1 | 15 |
| Cefotetan | 64 | 64 | 4–128 | 5 | 0 | 11 |
| Imipenem | 0.125 | 0.5 | 0.125–1 | 16 | 0 | 0 |
| Metronidazole | 0.125 | 0.25 | 0.125–1 | 16 | 0 | 0 |
| Clindamycin | 0.5 | 4 | 0.25–4 | 12 | 4 | 0 |
| Chloramphenicol | 8 | 16 | 4–16 | 14 | 2 | 0 |
| Ciprofloxacin | 0.5 | 64 | 0.5–64 | ND | ND | ND |
a
50% and 90%, MICs at which 50 and 90% of the isolates tested, respectively, were inhibited.
b
Categorization as susceptible (S), intermediate (I), or resistant (R) was performed using NCCLS-recommended breakpoints (for testing of anaerobic bacteria). ND, not determined.